Skip to main content

Table 2 Univariate analysis of CR

From: Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes

 

OR

95%CI

P

Gender (Male)

0.963

0.667,1.390

0.838

Age(<60)

0.915

0.692,1.209

0.509

Primary tumora

  

0.025

 Hepatic cance

1.182

0.359,5.581

0.783

 Ovarian cancer

0.159

0.037,0.693

0.014

 Cervical cancer

2.227

0.232,2.373

0.488

 Colorectal cancer

0.477

0.104,2.192

0.342

Others*

 Other metastases*

1.250

0.487,3.211

0.643

 Abnormal tumor Markers

1.494

1.022,2.185

0.054

Numberb

  

0.075

 1

0.336

0.070,1.616

0.173

 2

0.114

0.016,0.828

0.032

   3

   

Maximum diameterc

  

<0.001

 ≤ 3 cm

0.067

0.008,0.545

0.012

 3-5 cm

0.867

0.072,10.382

0.910

 ≥ 5 cm

   

Chemo ≥10*

1.270

0.471,3.472

0.639

Previous Radio*

1.444

0.371,5.623

0.596

Postoperative metastasis

1.337

0.979,1.827

0.094

D90 ≥ 120Gy#

1.108

0.629,1.648

0.943

Uniform density#

2.407

1.497,3.870

<0.001

Necrosis#

0.201

0.051,0.790

0.004

Regular morphology #

2.051

1.477,2.848

<0.001

Fusion#

0.411

0.212,0.799

0.001

Clear boundaries#

2.751

1.572,4.875

<0.001

Invasion of vessels visible on image#

0.241

0.095,0.607

<0.001

Significant enhancement#

0.616

0.393,0.966

0.013

Locationd

 Anterior# renal vein

0.361

0.138,0.942

0.034

 Posterior renal vein#

   

OAR<3*

1.221

0.945,1.577

0.168

Patients’ positione

  

0.772

 Supine

1.500

0.119,18.836

0.753

 Prone

1.056

0.090,12.418

0.966

Lateral position

 Puncture pathf

  

0.284

 Hepatic approach

2.586

0.767,8.590

0.126

 Abdominal wall

1.027

0.274,3.851

0.968

 Paravertebral approach

   
  1. a, b, c, d, e, fthe last variable as a reference; Others * Including renal cancer, esophageal cancer, nasopharyngeal cancer, gastric cancer, pancreatic cancer, duodenal cancer, ampullary carcinoma, endometrial cancer, bladder cancer, testicular cancer, ureteral cancer, renal pelvic carcinoma, lung cancer, embryo cancer; other metastases *, Refers to metastasis with other sites in addition to retroperitoneal lymph nodes before the treatment of 125I brachytherapy; Chemo *, Chemotherapy; Radio *, Radiotherapy; *OAR, The organs at risk; # The assessment of image feature was mainly completed by two radiologists(> 10 years of experiences in imaging diagnosis) in our center. When the Initially evaluation results were inconsistent, need to reach an agreement after negotiation